Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
19 pending office actions • 18 art units • 18 examiners • 0 of 19 (0%) have an AI response strategy ready • 19 patents granted in the last 365 days
National University Corporation Hokkaido University has 19 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 18 distinct examiners and 18 distinct art units, showing broad distribution across examination assignments.
RONEY, CELESTE A is the busiest examiner, with 2 pending actions. The difference between the action total and examiner total indicates that most matters are not concentrated with a single examiner. Portfolio management should therefore emphasize matter-level tracking, art-unit-specific analysis, and consistent technical support across responses.
The breadth of examiner and art-unit coverage can make unified prosecution themes useful, but it does not remove the need to tailor arguments to each assigned examination record.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (5%) |
| §101 + other | 2 (11%) |
| §103 only | 1 (5%) |
| §102 only | 1 (5%) |
| §112 only | 2 (11%) |
| Double-patenting + other | 3 (16%) |
| Multi-statute (no §101) | 9 (47%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RONEY, CELESTE A | 2 | 63.0% | +17.4% |
| JACKSON, MONIQUE R | 1 | 34.8% | +44.3% |
| KRUPICKA, ADAM C | 1 | 62.1% | +27.0% |
| PIPIC, ALMA | 1 | 54.8% | +54.3% |
| STAHL, MICHAEL J | 1 | 90.1% | +7.5% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| LEE, HOI YAN NMN | 1 | 37.5% | +76.2% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.0% |
| ARCIERO, ADAM A | 1 | 65.2% | -17.7% |
| HASTINGS, ALISON AZAR | 1 | 62.5% | +42.1% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18810979 | OPTICAL FILTER, METHOD OF MANUFACTURING OPTICAL FILTER, METHOD OF DESIGNING, DESIGN APPARATUS, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM | STAHL, MICHAEL J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396305 | COPPER CHELATOR, ANTICANCER AGENT AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR WILSON'S DISEASE | HASTINGS, ALISON AZAR | 15d |
| 18024955 | METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS | BOWERS, ERIN M | 27d |
| 19105942 | PRODUCTION METHOD FOR SLIGHTLY OXIDIZED COPPER-CONTAINING PARTICLES, AND SLIGHTLY OXIDIZED COPPER-COATED COPPER PARTICLES | JACKSON, MONIQUE R | — |
| 18719492 | METHOD FOR PURIFYING COMPOSITION | BECKHARDT, LYNDSEY MARIE | — |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | — |
| 18578874 | SULFIDE SOLID ELECTROLYTE | ARCIERO, ADAM A | — |
| 18282351 | METHOD FOR PRODUCING LAYERED COMPOSITE METAL OXIDE CRYSTAL MATERIAL | NGUYEN, KEVIN NMN | — |
| 18260488 | LIGNIN-DEGRADING CATALYST, METHOD FOR MANUFACTURING SAME, METHOD FOR DEGRADING LIGNIN, AND METHOD FOR REGENERATING LIGNIN-DEGRADING CATALYST | SAWYER, JENNIFER C | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18396305 | COPPER CHELATOR, ANTICANCER AGENT AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR WILSON'S DISEASE | HASTINGS, ALISON AZAR | 15d |
| 18921804 | METAL POROUS BODY, NITROUS OXIDE DECOMPOSITION ELEMENT, AND NITROUS OXIDE DECOMPOSITION APPARATUS | KRUPICKA, ADAM C | 34d |
| 19105942 | PRODUCTION METHOD FOR SLIGHTLY OXIDIZED COPPER-CONTAINING PARTICLES, AND SLIGHTLY OXIDIZED COPPER-COATED COPPER PARTICLES | JACKSON, MONIQUE R | — |
| 18851300 | LIPID NANOPARTICLES | PIPIC, ALMA | — |
| 18719492 | METHOD FOR PURIFYING COMPOSITION | BECKHARDT, LYNDSEY MARIE | — |
| 18708483 | ANTIVIRAL AGENT | LEE, HOI YAN NMN | — |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | — |
| 18561555 | LIPID NANOPARTICLES | RONEY, CELESTE A | — |
| Art Unit | Apps |
|---|---|
| 1612 | 2 |
| 1788 | 1 |
| 1784 | 1 |
| 1617 | 1 |
| 2874 | 1 |
| 1613 | 1 |
| 1693 | 1 |
| 1675 | 1 |
| 1727 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19105942 | PRODUCTION METHOD FOR SLIGHTLY OXIDIZED COPPER-CONTAINING PARTICLES, AND SLIGHTLY OXIDIZED COPPER-COATED COPPER PARTICLES | JACKSON, MONIQUE R | 1788 | §101§102§103§112 | Non-Final OA | — | Pending | Feb 24, 2025 |
| 18921804 | METAL POROUS BODY, NITROUS OXIDE DECOMPOSITION ELEMENT, AND NITROUS OXIDE DECOMPOSITION APPARATUS | KRUPICKA, ADAM C | 1784 | §112 | Final Rejection | 34d | Pending | Oct 21, 2024 |
| 18851300 | LIPID NANOPARTICLES | PIPIC, ALMA | 1617 | §112DP | Non-Final OA | — | Pending | Sep 26, 2024 |
| 18810979 | OPTICAL FILTER, METHOD OF MANUFACTURING OPTICAL FILTER, METHOD OF DESIGNING, DESIGN APPARATUS, AND NON-TRANSITORY COMPUTER-READABLE RECORDING MEDIUM | STAHL, MICHAEL J | 2874 | §102 | Non-Final OA | — | Pending | Aug 21, 2024 |
| 18719492 | METHOD FOR PURIFYING COMPOSITION | BECKHARDT, LYNDSEY MARIE | 1613 | §102§103§112 | Non-Final OA | — | Pending | Jun 13, 2024 |
| 18708483 | ANTIVIRAL AGENT | LEE, HOI YAN NMN | 1693 | §102§112DP | Non-Final OA | — | Pending | May 08, 2024 |
| 18293199 | PHARMACEUTICAL COMPOSITION FOR TREATING PERIPHERAL NERVE INJURY | CHERNYSHEV, OLGA N | 1675 | §102§112 | Non-Final OA | — | Pending | Jan 29, 2024 |
| 18578874 | SULFIDE SOLID ELECTROLYTE | ARCIERO, ADAM A | 1727 | §102§103 | Non-Final OA | — | Pending | Jan 12, 2024 |
| 18396305 | COPPER CHELATOR, ANTICANCER AGENT AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR WILSON'S DISEASE | HASTINGS, ALISON AZAR | 1627 | §101§102§103 | Final Rejection | 15d | Pending | Dec 26, 2023 |
| 18396272 | COMPOUND, MANUFACTURING METHOD THEREFOR, ANTIMICROBIAL AGENT, AND MEDICINAL DRUG | HIRAKIS, SOPHIA P | 1623 | §112 | Non-Final OA | — | Pending | Dec 26, 2023 |
| 18259348 | GFRALPHA1-CONTAINING NEURITE OUTGROWTH PROMOTER AND PHARMACEUTICAL COMPOSITION FOR INDUCING NERVE REGENERATION | BUTTICE, AUDREY L | 1647 | §103 | Non-Final OA | — | Pending | Dec 06, 2023 |
| 18561555 | LIPID NANOPARTICLES | RONEY, CELESTE A | 1612 | §103DP | Final Rejection | — | Pending | Nov 16, 2023 |
| 18282351 | METHOD FOR PRODUCING LAYERED COMPOSITE METAL OXIDE CRYSTAL MATERIAL | NGUYEN, KEVIN NMN | 1752 | §103§112 | Final Rejection | — | Pending | Sep 15, 2023 |
| 18260488 | LIGNIN-DEGRADING CATALYST, METHOD FOR MANUFACTURING SAME, METHOD FOR DEGRADING LIGNIN, AND METHOD FOR REGENERATING LIGNIN-DEGRADING CATALYST | SAWYER, JENNIFER C | 1691 | §102§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18024955 | METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS | BOWERS, ERIN M | 1653 | §101 | Final Rejection | 27d | Pending | Mar 06, 2023 |
| 18154575 | JAPANESE ENCEPHALITIS PREVENTIVE AGENT AND JAPANESE ENCEPHALITIS VACCINE AGENT | QIAN, CELINE X | 1637 | §102§112 | Non-Final OA | — | Pending | Jan 13, 2023 |
| 17989260 | LIPID MEMBRANE STRUCTURE FOR DELIVERY INTO SIRNA CELL | RONEY, CELESTE A | 1612 | §103§112Other | Non-Final OA | — | Pending | Nov 17, 2022 |
| 18052100 | TREATMENT DEVICE | MORAN, EDWARD JOHN | 3772 | §102§103§112 | Final Rejection | — | Pending | Nov 02, 2022 |
| 17996070 | METHOD FOR PRODUCING ORGANOMETALLIC NUCLEOPHILE AND REACTION METHOD USING ORGANOMETALLIC NUCLEOPHILE | HOU, FRANK S | 1692 | §102§103 | Final Rejection | — | Pending | Oct 12, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational University Corporation Hokkaido University has 19 pending office actions as of October 2026, spread across 18 art units and 18 examiners.
Celeste A Roney has the most, with 2 of National University Corporation Hokkaido University's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
